Comparative efficacy of photodynamic therapy (PDT), ranibizumab, aflibercept monotherapy, and combination therapies for polypoidal choroidal vasculopathy: a network meta-analysis of randomized controlled trials
Abstract Purpose Polypoidal choroidal vasculopathy (PCV) is recognized as a distinct clinical condition characterized by persistent serous leakage, bleeding, and the presence of polypoidal lesions beneath the retinal pigment epithelium (RPE). This systematic review and meta-analysis aimed to evaluat...
Saved in:
| Main Authors: | Miguel A. Quiroz-Reyes, Erick A. Quiroz-Gonzalez, Miguel A. Quiroz-Gonzalez, Virgilio Lima-Gomez |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Ophthalmology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12886-025-04249-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Two-year results of switching to intravitreal administration of faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration
by: Masaaki Saito, et al.
Published: (2025-08-01) -
New Drugs for the Treatment of DME and the Role of Biomarkers in Predicting Their Effectiveness
by: M. V. Budzinskaya, et al.
Published: (2023-01-01) -
Polypoidal Choroidal Vasculopathy Treatment: Photodynamic Therapy, Anti-VEGF Monotherapy or Combination. Review of Clinical Studies
by: E. K. Pedanova, et al.
Published: (2019-06-01) -
Early optical coherence tomography biomarkers for tailored frequency of intravitreal aflibercept in neovascular age-related macular degeneration
by: Gyeongsoo Lim, et al.
Published: (2025-03-01) -
Switching to Faricimab for Polypoidal Choroidal Vasculopathy with Real-World Outcomes in Refractory Cases – The FAR-PEARL Study Report 1
by: Fong KC, et al.
Published: (2025-07-01)